Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Dostal

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
American Journal of Physiology. Heart and Circulatory Physiology|August 12, 2025
The sodium/glucose cotransporter 2 inhibitor empagliflozin is a pharmacological chaperone of cardiac Na<sub>v</sub>1.5 channelsJakob Sauer, Jessica Marksteiner, Martin Hohenegger, et al.
American Journal of Physiology. Heart and Circulatory Physiology|August 11, 2025
Inhibition of tenascin C rescues abnormally reduced Na currents in dystrophin-deficient ventricular cardiomyocytesJessica Marksteiner, Jakob Sauer, Martin Hohenegger, et al.
The American Journal of Pathology|December 14, 2025
Targeting Skeletal Muscle in Duchenne Muscular Dystrophy: Integrating in Silico and Experimental Approaches to Sodium-Glucose Cotransporter-2 InhibitionChristopher Dostal, Johanna Reiner, Ana Isabel Antunes Goncalves, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 30, 2025
Dapagliflozin enhances hemodynamic and metabolic recovery following cardioplegic arrest in the isolated working mouse heartChristopher Dostal, Johanna Reiner, Daniel Spona, et al.
Scientific Reports|March 16, 2025
Chronic administration of ivabradine improves cardiac Ca handling and function in a rat model of Duchenne muscular dystrophyJessica Marksteiner, Christopher Dostal, Janine Ebner, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
American Journal of Physiology. Heart and Circulatory Physiology|August 12, 2025
The sodium/glucose cotransporter 2 inhibitor empagliflozin is a pharmacological chaperone of cardiac Na<sub>v</sub>1.5 channelsJakob Sauer, Jessica Marksteiner, Martin Hohenegger, et al.
American Journal of Physiology. Heart and Circulatory Physiology|August 11, 2025
Inhibition of tenascin C rescues abnormally reduced Na currents in dystrophin-deficient ventricular cardiomyocytesJessica Marksteiner, Jakob Sauer, Martin Hohenegger, et al.
The American Journal of Pathology|December 14, 2025
Targeting Skeletal Muscle in Duchenne Muscular Dystrophy: Integrating in Silico and Experimental Approaches to Sodium-Glucose Cotransporter-2 InhibitionChristopher Dostal, Johanna Reiner, Ana Isabel Antunes Goncalves, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 30, 2025
Dapagliflozin enhances hemodynamic and metabolic recovery following cardioplegic arrest in the isolated working mouse heartChristopher Dostal, Johanna Reiner, Daniel Spona, et al.
Scientific Reports|March 16, 2025
Chronic administration of ivabradine improves cardiac Ca handling and function in a rat model of Duchenne muscular dystrophyJessica Marksteiner, Christopher Dostal, Janine Ebner, et al.
Pageof 2